Cancer Genetics, Inc. Adds Additional Kidney Cancer Patent to its Portfolio
February 26 2014 - 7:30AM
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an
emerging leader in DNA-based diagnostics, today announced that the
United States Patent and Trademark Office (USPTO) has allowed its
patent claims related to the Company's proprietary methods for
detecting the subtype of renal cortical neoplasm present in a
patient sample. The patent application (14/078,726) is expected to
obtain an issued patent number during the second quarter of 2014.
This latest patent builds on the intellectual property portfolio
the Company has already gained for kidney cancer diagnostics. In
December 2013, Cancer Genetics was awarded U.S. Patent No.
8,603,948, covering a panel of proprietary probes directed to
detecting various types of renal cortical neoplasms. The
methodology that has received allowance for patent in this latest
application utilizes those patented probes.
"This latest application protects the unique methodologies
developed by our team, while expanding our robust intellectual
property portfolio in the field of molecular diagnostics and
clinical genomics," stated Panna Sharma, CEO of CGI. "By improving
detection of the specific subtype of a patient's kidney cancer, we
are able to offer a truly personalized approach that allows us to
provide more value for renal cancer patients and their care
providers."
There are over 60,000 new cases of kidney cancer each year in
the U.S. and approximately 14,000 related deaths. Kidney cancer is
the sixth-leading cancer type in males in the U.S., and its
incidence rate is increasing at nearly 4% per year. There is a
significant need to reduce the time to initial treatment and, at
the same time, establish new non-invasive genomic methods to aid in
accurate diagnosis and treatment selection.
New data further validating CGI's UroGenRA™-Kidney test,
generated as part of a collaborative study conducted with the
Cleveland Clinic, will be presented on March 3 at the annual United
States & Canadian Academy of Pathology (USCAP) meeting. In the
study, 191 pathology specimens from renal cancer patients were
analyzed using CGI's proprietary genomic microarray test, which
enables accurate classification of kidney cancer among the four
major subtypes and predicts whether the cancer is benign or
malignant. The test has been validated to work across sample types
ranging from fine-needle aspirate to paraffin-embedded and
formalin-fixed tissue, making it widely usable for both new cases
as well as cases that are not diagnosable using traditional
methods.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
lab is focused entirely on maintaining clinical excellence and is
both CLIA certified and CAP accredited and has licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute. For further information, please
see www.cancergenetics.com.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development and potential opportunities for Cancer Genetics, Inc.
products and services, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to,
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, risks of cancellation of customer contracts or
discontinuance of trials, uncertainty in the results of clinical
trials or regulatory approvals, need and ability to obtain future
capital, maintenance of intellectual property rights and other
risks discussed in the Company's Form 10-Q for the quarter ended
September 30, 2013 and other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. Cancer Genetics disclaims any obligation to
update these forward-looking statements.
CONTACT: Investor Relations
Michael Rice
Life Science Advisors LLC
646-597-6979
Media Relations
RedChip Companies, Inc.
Paul Kuntz, 800-733-2447, ext. 105
paul@redchip.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024